Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00030563 · ClinicalTrials.gov registry record · Phase 2

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

A Phase 2 study of Colorectal Cancer and Metastatic Cancer, sponsored by University of Washington.

Completed
Registry status
Phase 2
Development phase
3
Study locations

NCT00030563 is a Phase 2 study of Colorectal Cancer and Metastatic Cancer that has completed, run by University of Washington. The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00030563, a Phase 2 study of Colorectal Cancer and Metastatic Cancer, has completed, sponsored by University of Washington.

COMPLETED
Registry status
Phase 2
Development phase
3
Study locations

Study Summary

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug after surgery and radiofrequency ablation may kill any remaining tumor cells. PURPOSE: Phase II trial to determine the effectiveness of surgery with or without radiofrequency ablation followed by irinotecan in treating patients who have colorectal cancer that is metastatic to the liver.

Interventions

  • PROCEDURE conventional surgery
  • PROCEDURE adjuvant therapy
  • DRUG irinotecan hydrochloride
  • PROCEDURE radiofrequency ablation

Study Locations (3)

Ohio

  • Ireland Cancer Center - Cleveland

Washington

  • University of Washington School of Medicine - Seattle

Ontario

  • Princess Margaret Hospital - Toronto

Trial Details

FieldValue
Start Date 2001-05
Est. Completion 2005-10
Phase Phase 2

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT00030563

The ClinicalTrials.gov registry entry for NCT00030563 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which conventional surgery is the first listed.

NCT00030563 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Ohio, Washington, Ontario.

Frequently Asked Questions

What is clinical trial NCT00030563 about?

NCT00030563 is a clinical study titled "Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver". RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy dr...

What is the current status of trial NCT00030563?

This trial is currently completed. It is a Phase 2 study. The study started on 2001-05. Estimated completion is 2005-10.

What conditions does trial NCT00030563 study?

This clinical trial studies the following conditions: Colorectal Cancer, Metastatic Cancer.

What interventions are being tested in trial NCT00030563?

The interventions under investigation include: conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), irinotecan hydrochloride (DRUG), radiofrequency ablation (PROCEDURE).

Who is sponsoring clinical trial NCT00030563?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00030563 being conducted?

This trial has 3 study locations across Ohio, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.